Reduced glomerular filtration rate ranked similarly to high total cholesterol as a risk factor for disability-adjusted life years.
Baseline nutritional status does not influence the effect of randomized long-term multivitamin use on major CVD events.
The largest numbers of diet-related cardiometabolic deaths were related to high sodium, low nuts/seeds, high processed meats, low seafood omega-3 fats, low vegetables, low fruits, and high SSBs.
The primary outcome of CVD occurred in 303 participants (11.8%) in the vitamin D group and 293 participants (11.5%) in the placebo group.
Hyperglycemia from genetics increases the risk of coronary artery disease separately from type 2 diabetes and other CAD risk factors.
Statin intolerance was associated with a 36% higher rate of recurrent MI, a 43% higher rate of CHD events, and a 15% lower rate of all-cause mortality.
Action taken to mitigate risks associated with ESA use and changes in payment policy did not result in a relative increase in death or major cardiovascular events.
Both evolocumab and inclisiran reduced the risk of cardiovascular events and lowered LDL cholesterol levels.
The USPSTF guidelines focus statin recommendations on 38% of high-risk African American individuals at the expense of not recommending treatment in nearly 25% of African Americans.
Men taking PDE5 lowered their risk of hospitalization and mortality after a heart attack by 33%.
In short-term treatment duration, there was no increased risk of myocardial infarction stroke or heart failure using DPP-4i vs SU/TZD.
Patients with early and frequent nephrology visits before dialysis initiation had about a 10% lower risk for major adverse cardiovascular events.
No evidence to determine whether taking herbal medications cause complications among patients with CVD.
No deaths, lead failures, losses of capture, or ventricular arrhythmias occurred during MRI.
Plasma TMAO levels among patients predict both near- and long-term risks of incident cardiovascular events.
Participants with high TG and low HDL levels had a 1.32-fold greater HR for CHD than those with normal TG and normal HDL levels.
In a large study, testosterone replacement therapy was associated with a 33% lower risk of cardiac and stroke events among hypogonadal men.
The presence of CAC among individuals aged between 32 and 46 years was associated with increased risk of fatal and nonfatal CHD during 12.5 years of follow-up.
Those without traditional cardiovascular risk factors are disproportionately prone to these cardiac diseases in the setting of alcohol abuse.
Adjusted rates of hospitalization for AF increased by almost 1% per year between 1999 and 2013.
Irregular eating patterns appear less favorable for achieving a healthy cardiometabolic profile.
Baseline LDL-C was lower in patients with LDL-C <25 versus ≥25 mg/dl.
Patients with an eGFR below 60 mL/min/1.73 m2 were more likely to die in the hospital or be discharged to hospice.
Higher RHR was significantly associated with all-cause mortality and cardiovascular events in older but not younger participants.
The potential safety signals of myopathies and liver injury raise the hypothesis that the safety profile of RYR is similar to that of statins.
Dialysis facilities with the least control of PTH, Ca, and P had the greatest risks.
Sitagliptin did not significantly impact the primary composite, death, heart failure hospitalization, severe hypoglycemia, rates of acute pancreatitis and pancreatic cancer, or serious adverse events.
New guidelines suggest aiming for a systolic pressure less than 150 mm Hg in hypertensive individuals aged 60 or older.
The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes.
Mortality was more frequently due to noncardiovascular causes, and predictors of noncardiovascular mortality included factors traditionally associated with cardiovascular mortality.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)